Loading...
•
Sep 30, 2021
Celcuity Q3 2021 Earnings Report
Announced financial results for the third quarter ended September 30, 2021 and summarized recent business progress.
Key Takeaways
Celcuity Inc. reported a net loss of $6.0 million for the third quarter of 2021, compared to a net loss of $2.5 million for the third quarter of 2020. The company's cash and cash equivalents were $90.4 million as of September 30, 2021.
Initiated preparation for a Phase 3 clinical trial evaluating gedatolisib in combination with Ibrance and Faslodex in patients with ER+/HER2- advanced or metastatic breast cancer, expected to activate in the first half of 2022.
Site identification and feasibility activities are underway for the Phase 3 clinical trial.
Updated results from the Phase 1b clinical trial in patients with ER+/HER2- advanced breast cancer will be presented at the San Antonio Breast Cancer Symposium in December.
Entered into a clinical trial collaboration with University of Rochester Wilmot Cancer Center and Puma to evaluate CELsignia® selected patients with advanced breast cancer.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...